Author: Editor

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Suresh Senan discusses new radiotherapy techniques for the treatment of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Jesus Corral discusses how best to manage adverse effects when utilizing immunotherapy for the treatment of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Joachim G. Aerts discusses the utilization of immune checkpoint inhibitors in the treatment of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Sandrine Aspeslagh elucidates the basis for immunotherapy in lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Paul Van Schil arguest that trimodality therapy is the optimal approach for stage III non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Ugo Pastorino discusses primary and secondary prevention of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Stefano Gasparini discusses how best to use endobronchial and other techniques to optimize diagnosis and therapy in lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Ramon Rami-Porta discusses updates on the TNM staging system. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the next steps and future development for vyxeos in AML, which include a better understanding of the drug and its impact on overall survival in other subsets of AML.

Jeffrey E. Lancet, MD of Moffitt Cancer Center gives an overview of a phase 3 randomized trial, which focused on the use of vyxeos (CPX-351) compared to cytarabine and daunorubicin (7+3) in older patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the impact of vyxeos on future clinical practice.

Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses common questions hes been asked regarding the safety and efficacy of vyxeos in AML patients.

Karen Smith, MD outlines the safety and efficacy of Vyxeos the newly approved chemotherapy for the treatment of adults with newly-diagnosed t-AML or AML-MRC. The FDA approval is based on data from a pivotal Phase 3 clinical trial that evaluated the efficacy and safety of Vyxeos compared to cytarabine and daunorubicin (7+3) in 309 patients 60 to 75 years of age with newly diagnosed t-AML or AML-MRC. In the Vyxeos arm, patients received 44mg/100mg per m2 (daunorubicin and cytarabine) liposome intravenously via a 90 minute infusion on days 1, 3 and 5 of induction (days 1 and 3 if a…

Karen Smith answers some common questions and concerns about the newly FDA approved Vyxeos for the treatment of adults with newly-diagnosed t-AML or AML-MRC. The FDA approval is based on data from a pivotal Phase 3 clinical trial that evaluated the efficacy and safety of Vyxeos compared to cytarabine and daunorubicin (7+3) in 309 patients 60 to 75 years of age with newly diagnosed t-AML or AML-MRC. In the Vyxeos arm, patients received 44mg/100mg per m2 (daunorubicin and cytarabine) liposome intravenously via a 90 minute infusion on days 1, 3 and 5 of induction (days 1 and 3 if a…

The U.S. Food and Drug Administration (FDA) has approved VyxeosTM (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Leukemia (AML), a rapidly progressing and life-threatening blood cancer. Vyxeos is indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC. The FDA approval is based on data from a pivotal Phase 3 clinical trial that evaluated the efficacy and safety of Vyxeos compared to cytarabine and daunorubicin (7+3) in 309 patients 60 to 75 years of age with newly diagnosed t-AML or AML-MRC. In the Vyxeos arm, patients received 44mg/100mg per…

Dr. Catriona Jamieson, from Moores Cancer Center at UC San Diego Health, joined Patient Power to discuss considerations when choosing to participate in a clinical trial. Dr. Jamieson sheds light on the necessity of ongoing MPN clinical trials, particularly for myelofibrosis, as well as how to talk to your doctor about this treatment option. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Alex Spira, Director of the Virginia Cancer Specialist Research Institute and ASCO President Dr. Bruce Johnson, discuss research around promising clinical trials to help patients and care partners learn how to be proactive in order to get tomorrows medicine today. Leading patient advocate Matt Ellefson of SURVIVIEiT® joins the panel to share his passion and tips for making sure patients advocate for themselves from the start. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Daniela Bota, MD of UC Irvine Health discusses the use of neratinib and capecitabine in patients with breast cancer brain metastases at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 1005: TBCRC 022: Phase II Trial of Neratinib + Capecitabine for Patients (pts) with Human Epidermal Growth Factor Receptor 2 (HER2+) Breast Cancer Brain Metastases (BCBM)

Daniela Bota, MD of UC Irvine Health discusses the results of nivolumab versus nivolumab plus ipilimumab in patients with Melanoma at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 9508: A Randomized Phase II Study of Nivolumab or Nivolumab Combined with Ipilimumab in Patients (pts) with Melanoma Brain Metastases (mets): The Anti-PD1 Brain Collaboration (ABC)

Daniela Bota, MD of UC Irvine Health gives an overview of the final results of the TAVAREC trial, which studied temozolomide and bevacizumab in patients with glioma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 2009: Final Results of the EORTC Brain Tumor Group Randomized Phase II TAVERAC Trial on Temozolomide with or without Bevacizumab in 1st Recurrance Grade II/III Glioma without 1p/19q co-deletion

Daniela Bota, MD of UC Irvine Health discusses a phase II clinical trial called the CEVOREM study, which focused on everolimus and octreotide in patients with meningioma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 2011: A Phase II of Everolimus and Octreotide for Patients with Refractory and Documented Progressive Meningioma (CEVOREM)

Daniela Bota, MD of UC Irvine Health gives an overview of the AURA3 trial and the use of osimertinib in patients with advanced non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 9005: CNS Response to Osimertinib in Patients (pts) with T790M-Positive Advanced NSCLC: Data from a Randomized Phase III Trial (AURA3)

Daniela Bota, MD of UC Irvine Health gives her take on Senator John McCain’s recent diagnosis of glioblastoma. She further explains the common symptoms of glioblastoma, the importance of participating in clinical trials, and the most effective and common treatment options for those who are affected by this specific cancer.

Viola Zhu, MD, PhD of UC Irvine Health discusses the CTONG 1104 trial and the use of gefitinib for adjuvant treatment of patients with resected EGFR+ non-small cell lung cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 8500: CTONG 1104: Adjuvant Treatment with Gefitinib in Resected EGFR+ NSCLC.

Viola Zhu, MD, PhD of UC Irvine Health discusses the AvaALL trial and the use of bevacizumab beyond progression in patients with non-small cell lung cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 90040: AvaALL: Use of Bevacizumab Beyond Progression

Viola Zhu, MD, PhD of UC Irvine Health gives an overview of the ARCHER 1050 trial in EGFR+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract LBA9007: ARCHER 1050: Dacomitinib versus Gefitinib in EGFR+ NSCLC at the First Line Setting

Viola Zhu, MD, PhD of UC Irvine Health discusses the ALEX trial and the use of alectinib and crizotinib in ALK+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract LBA9008: ALEX: Alectinib versus Crizotinib in ALK+ NSCLC at the First-Line Setting.

Rita Mehta, MD of UC Irvine Health discusses the take-home message of PALOMA-1 and the impact on clinical practice at the 2017 MOASC Spotlight on Oncology in Huntington Beach, CA. Abstract 1001: Overall Survival: Palbociclib in Combination with Letrozole versus Letrozole Alone for Frontline Treatment of ER+/HER2-Advanced Breast Cancer PALOMA-1; TRIO-18

Rita Mehta, MD of UC Irvine Health gives an overview of the PALOMA-1 trial and the use of palbociclib and letrozole in the treatment of ER+ and HER2-advanced breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 1001: Overall Survival: Palbociclib in Combination with Letrozole versus Letrozole Alone for Frontline Treatment of ER+/HER2-Advanced Breast Cancer PALOMA-1; TRIO-18

Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of olaparib in HER2 negative metastatic breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract LBA4: OlympiAD: Olaparib versus Chemotherapy in HER2 Negative Metastatic Breast Cancer and a Germline BRCA Mutation

Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib and fulvestrant in advanced HR+/HER2 negative breast cancer progressing patients following prior endocrine therapy. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 1000: MONARCH 2: Abemaciclib with Fulvestrant in Patients withs HR+/HER2-Advanced Breast Cancer who Progressed on Endocrine Therapy

Rita Mehta, MD of UC Irvine Health gives an overview of the APHINITY trial and the use of pertuzumab as adjuvant therapy for patients with HER2+ early breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract: LBA500: APHINITY trial (BIG 4-11): Pertuzumab as Adjuvant Therapy in HER2-Positive Early Breast Cancer.

Farshid Dayyani, MD, PhD of UC Irvine Health discusses sidedness in colorectal cancer tumors at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Farshid Dayyani, MD, PhD of UC Irvine Health gives an overview of the IDEA trial at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Farshid Dayyani, MD, PhD of UC Irvine Health discusses the BRAF trial and explains how to overcome resistance to anti-EGFR therapy in patients with metastatic colorectal cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Farshid Dayyani, MD, PhD of UC Irvine Health discusses the Immunotherapy Trials, the Keynote trial and the Checkmate trial, at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Farshid Dayyani, MD, PhD of UC Irvine Health gives an overview of the FLOT trial, a practice-changing clinical trial in gastroesophageal carcinoma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Sarmen Sarkissian, MD of UC Irvine Health discusses the highlights in prostate cancer research, specifically a phase III clinical trial on the use of Abiraterone in the treatment of prostate cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Sarmen Sarkissian, MD of UC Irvine Health discusses the highlights in kidney cancer research specifically a phase II study on the use of Atezolizumab and Bevacizumab for patients with locally advanced or metastatic renal cell carcinoma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

As part of a recent MPN Town Meeting in partnership with Robert H. Lurie Comprehensive Cancer Center in Chicago, Drs. Brady Stein and Naveen Pemmaraju discuss how myeloproliferative neoplasms (MPNs)essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) are diagnosed. The experts discuss the necessary blood tests, including platelet counts, and provide a thorough explanation of bone marrow biopsy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Tanja Cufer discusses the treatment of elderly and PS2 patients with lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Paul Baas discusses the latest treatment options for malignant mesothelioma. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Nicholas Girard discusses the treatment of carcinoids, large cell neuroendocrine carcinoma, thymoma, and thymic carcinomas. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Egbert F. Smit discusses new treatment options for small cell lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Luis Paz-Ares discusses treatment options in the first- and second-line settings for squamous cell carcinoma of the lung. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Sanjay Popat discusses mutation-independent approaches to the treatment of adenocarcinoma, including maintenance therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Fernando López-Ríos arguest that liquid biopsy will not replace tissue biopsy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Thomas Newsom-Davis argues that liquid biopsy will replace tissue biopsy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Luis Paz-Ares discusses HER-2, BRAF, KRAS, and MET tumors. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.